The platinum(II) complex [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+^{2+} (56MeSS, compound 5 in the source study) and its Pt(IV) prodrug derivatives kill cancer cells at sub-micromolar concentrations through a multimodal mechanism of action whose most distinctive component is a marked reorganization of the microtubule cytoskeleton: platinum accumulates preferentially in the cytoskeletal fraction, cells arrest in G2/M, and purified tubulin assembles into aggregated, slowly depolymerizing bundles. The 2019 study that established this phenotype left its molecular basis unresolved, and no subsequent study has resolved it. Three interlocking questions are open: whether the compounds bind tubulin directly at a specific site or act indirectly to promote polymer aggregation; whether microtubule aggregation is causally necessary for cell death at pharmacological concentrations; and what reductant chemistry activates the Pt(IV) prodrugs inside cells.

Background

Clinically used platinum drugs — cisplatin, carboplatin, and oxaliplatin — are square-planar Pt(II) complexes that kill cells mainly by forming coordination adducts on nuclear DNA, blocking replication and transcription. Their dose-limiting toxicity, inherent and acquired resistance, and narrow tumor spectra motivate two main design alternatives. The first is the Pt(IV) prodrug strategy: Pt(IV) complexes are octahedral and kinetically inert, so they survive extracellular conditions and oral administration better than Pt(II) drugs, and are converted inside cells by chemical reduction to the active square-planar Pt(II) species; their two axial ligands can additionally carry bioactive payloads (the "multi-action" prodrug concept). The second alternative is the family of "unconventional" cationic Pt(II) metallointercalators of formula [Pt(A)(P)]2+^{2+} — metallointercalators are planar metal complexes that insert between adjacent base pairs of nucleic acids — which pair a diaminocyclohexane (DACH) carrier ligand with a planar aromatic phenanthroline-type ligand; the prototypical member is 56MeSS, which carries 5,6-dimethyl-1,10-phenanthroline (earlier papers write the same cation as 56MESS). Work before 2019 had already shown by transcriptomic and proteomic methods that 56MeSS affects mitochondrial and cytoskeletal proteins and the cell cycle, distinguishing it mechanistically from cisplatin-like DNA-damaging agents.

The source study (Kostrhunová et al., J. Med. Chem. 2019, 62, 5176–5190) compared 56MeSS (compound 5) and three Pt(IV) derivatives (6, with axial phenylbutyrate ligands — phenylbutyrate being a histone-deacetylase-inhibitor fragment with epigenetic activity; 7, with octanoate; 8, with both) against oxaliplatin (1) and its Pt(IV) analogues (2–4). Its key findings were: half-maximal inhibitory concentrations (IC50 values — the concentration at which cell viability is halved) of 0.24 μM for 5 and 0.06–0.08 μM for 6–8 in MDA-MB-231 triple-negative breast cancer cells, with nanomolar potency in A2780 ovarian and HCT-116 colorectal carcinoma cells; after 6 h treatment, 73–76% of cell-associated platinum resided in the cytoskeletal fraction (versus predominantly membrane-localized platinum for the oxaliplatin series); impedance-based time-dependent cell response profiles (TCRPs — label-free, real-time morphological/impedance fingerprints used to classify mechanisms of action) clustered with microtubule-modulating agents rather than DNA-synthesis inhibitors; cells accumulated in the G2/M phase of the cell cycle (the pre-mitotic and mitotic phases; from 16% to 30–44% at 48 h), the hallmark of spindle poisons (drugs that disrupt the mitotic spindle of microtubules and thereby arrest dividing cells); growth inhibition was synergistic with the microtubule inhibitors nocodazole and vinblastine (combination index ≈ 0.5–0.8, where values below 1 indicate synergy) but merely additive with actin-directed agents (phalloidin, cytochalasin D); in cell-free assays with purified porcine brain tubulin, the compounds slowed the initial polymerization rate, raised steady-state light scattering, and slowed cold-induced depolymerization; atomic force microscopy showed bundles, knots, and coils instead of normal fibrillar microtubules; and treated cells contained increased polymerized tubulin. Genetic controls connected cytotoxicity of the oxaliplatin series to DNA damage (a roughly tenfold sensitivity difference between Chinese hamster ovary (CHO) cells proficient and deficient in nucleotide excision repair, the pathway that removes bulky platinum–DNA adducts) but not that of the 5-series (difference ≈ 1.5-fold), and DNA platination by the Pt(IV) derivatives required a reducing agent in vitro, supporting activation by reduction.

What the study did not do is equally important for the present problem. It identified no molecular target at the tubulin/microtubule level: no binding assay against the classical tubulin sites (the taxane, vinca-alkaloid, and colchicine pockets — the three ligand-binding sites on the tubulin heterodimer at which approved microtubule drugs bind), no mass-spectrometric or structural identification of a platinum–tubulin adduct, and no test of an indirect mediator. Its cell-free and cellular tubulin assays used 20–80 μM compound — roughly 100–300-fold above the cellular IC50 values, and at up to about a 2:1 compound-to-tubulin ratio — a range in which nonspecific protein aggregation is a recognized artifact. The intracellular reduction of the Pt(IV) derivatives was inferred from ascorbate-dependent DNA binding in vitro and from platinum found on cellular DNA, never measured directly. And no perturbation experiment (rescue, loss-of-function, or target-blocking) established that the microtubule effect is necessary for cell death. The authors accordingly presented the cytoskeleton-aggregation mechanism as a functionally important, but mechanistically unexplained, component of a multimodal mechanism of action.

Problem Statement

For 56MeSS — [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+^{2+}, a platinum(II) metallointercalator (a planar metal complex that inserts between adjacent base pairs of DNA; earlier literature writes the same cation as 56MESS) — and its Pt(IV) prodrug derivatives (the phenylbutyrate- and octanoate-axial complexes 6–8 of the source study), the mechanism by which they disrupt microtubule organization is unresolved. The question, in the source study's own scope, has three interlocking parts. (1) Molecular target identity at the tubulin/microtubule level: do 56MeSS, and the platinum species actually generated inside cells from its Pt(IV) prodrugs, bind directly and specifically to tubulin — at one of the canonical ligand pockets on the tubulin heterodimer (the taxane, vinca-alkaloid, or colchicine sites, where approved microtubule drugs bind) or at a noncanonical site — or do they act indirectly (for example through microtubule-associated proteins, altered tubulin post-translational modification, or nonspecific electrostatic and crosslinking interactions with the polymer) to produce the observed aggregated and slowly depolymerizing microtubule assemblies? (2) Causal necessity and relative contribution: is the induction of microtubule aggregation and slowed depolymerization, at concentrations comparable to the sub-micromolar cellular IC50 values (the concentrations that halve cell viability in culture), necessary for the cytotoxicity of these compounds, and, for the Pt(IV) prodrugs, how does its contribution weigh against nuclear-DNA damage and the mitochondrial and epigenetic effects of their axial ligands? (3) Activation chemistry of the Pt(IV) prodrugs: what are the chemical identity, subcellular location, and kinetics of the intracellular reduction and processing pathways that convert the Pt(IV) derivatives into the species that engage these targets? Each of these parts is separately answerable and calls for a mechanism-level determination supported by the cited findings or by an explicit experimental route, while a complete resolution of the problem requires all three.

References

  1. Kostrhunová H, Zajac J, Novohradský V, Kasparková J, Malina J, Aldrich-Wright JR, Petruzzella E, Sirota R, Gibson D, Brabec V. A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. Journal of Medicinal Chemistry 2019, 62(10), 5176–5190. DOI: 10.1021/acs.jmedchem.9b00489. https://doi.org/10.1021/acs.jmedchem.9b00489
  2. Kostrhunová H, McGhie BS, Marková L, Nováková O, Kasparková J, Aldrich-Wright JR, Brabec V. Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells. Journal of Medicinal Chemistry 2023, 66(12), 7894–7908. DOI: 10.1021/acs.jmedchem.3c00269. https://doi.org/10.1021/acs.jmedchem.3c00269
  3. Elias MG, Fatima S, Mann TJ, Karan S, Mikhael M, de Souza P, Gordon CP, Scott KF, Aldrich-Wright JR. Anticancer Effect of PtIIPHENSS, PtII5MESS, PtII56MESS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer. Cancers 2024, 16(14), 2544. DOI: 10.3390/cancers16142544. https://doi.org/10.3390/cancers16142544
  4. Elias MG, Aputen AD, Fatima S, Mann TJ, Karan S, Mikhael M, de Souza P, Gordon CP, Scott KF, Aldrich-Wright JR. Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells. International Journal of Molecular Sciences 2024, 25(15), 8252. DOI: 10.3390/ijms25158252. https://doi.org/10.3390/ijms25158252
  5. Kee JX, Yau JN, Kumar Muthuramalingam RP, Wang X, Chng WH, Lopez-Sanchez A, Tay KK, Deng L, Gibson D, Bertrand HC, Adriani G, Ang WH, Pastorin G. Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs. Chemical Reviews 2025, 125(21), 10248–10341. DOI: 10.1021/acs.chemrev.5c00041. https://doi.org/10.1021/acs.chemrev.5c00041
  6. Ferreira ALdS, Dantas BB, Souza-Ferrari JD, Filho EBA. Potential Biological Targets of Anticancer Metal-Based Drug Candidates: A Systematic Review. Drug Development Research 2026, 87(3), e70315. DOI: 10.1002/ddr.70315. https://doi.org/10.1002/ddr.70315
  7. Moretto J, Chauffert B, Ghiringhelli F, Aldrich-Wright JR, Bouyer F. Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator. Investigational New Drugs 2011, 29(6), 1164–1176. DOI: 10.1007/s10637-010-9461-z. https://doi.org/10.1007/s10637-010-9461-z
  8. Garbutcheon-Singh KB, Myers S, Harper BW, Ng NS, Dong Q, Xie C, Aldrich-Wright JR. The effects of 56MESS on mitochondrial and cytoskeletal proteins and the cell cycle in MDCK cells. Metallomics 2013, 5(8), 1061. DOI: 10.1039/c3mt00023k. https://doi.org/10.1039/c3mt00023k
  9. Wang S, Higgins VJ, Aldrich-Wright JR, Wu MJ. Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator. Journal of Chemical Biology 2012, 5(2), 51–61. DOI: 10.1007/s12154-011-0070-x. https://doi.org/10.1007/s12154-011-0070-x
  10. Chen S, Zhou Q, Ng K, Xu Z, Xu W, Zhu G. Advances in technical strategies for monitoring the reduction of platinum(IV) complexes. Inorganic Chemistry Frontiers 2024, 11(11), 3085–3118. DOI: 10.1039/d4qi00459k. https://doi.org/10.1039/d4qi00459k
  11. Schmidt C, Babu T, Kostrhunová H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? Journal of Medicinal Chemistry 2021, 64(15), 11364–11378. DOI: 10.1021/acs.jmedchem.1c00706. https://doi.org/10.1021/acs.jmedchem.1c00706
  12. Malina J, Kostrhunová H, Aldrich-Wright JR, Brabec V. Antitumor platinum(II) complex 56MESS binds to DNA G-quadruplexes, downregulates expression of c-MYC and k-RAS oncogenes, and triggers DNA damage in cancer cells. Chemico-Biological Interactions 2025, 416, 111534. DOI: 10.1016/j.cbi.2025.111534. https://doi.org/10.1016/j.cbi.2025.111534